RELYPSA INC (RLYP)
(Delayed Data from NSDQ)
$31.99 USD
+0.02 (0.06%)
Updated Aug 31, 2016 04:00 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[RLYP]
Reports for Purchase
Showing records 1 - 20 ( 113 total )
Industry: Medical - Generic Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Generic Drugs
Downgrading Our Rating to NEUTRAL and Reducing Our Price Target to $32 as Tender Offer Close to Completion
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Medical - Generic Drugs
Q2 Financials Were Uneventful; We Continue to Believe the Value of Veltassa Supports a Higher Bid
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Generic Drugs
Galenica Acquires Relypsa; Offer Price Matches Our PT; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Generic Drugs
Relypsa (RLYP - OUTPERFORM): Relypsa and Galenica Agree to $32 per Share Acquisition; Reiterate OUTPERFORM and $51 Price Target As We See Room for Another Bidder.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
Veltassa Script Growth Accelerates in June; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 25.00
Industry: Medical - Generic Drugs
June Prescription Figures Point to Steady Growth; Reiterate OUTPERFORM and $51 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Generic Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Medical - Generic Drugs
May Prescription Figures Point to Continued Uptake;Reiterate OUTPERFORM and $51 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Medical - Generic Drugs
KOL Nephrologist Considers Veltassa to be Best-In- Class Among Hyperkalemia Treatments; Reiterate OUTPERFORM and $51 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
We See Improving Investor Sentiment Post ZS-9 CRL; Reiterate OUTPERFORM and $51 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00
Industry: Medical - Generic Drugs
June and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Generic Drugs
ZS-9 Loses its Halo: CRL Cites Manufacturing Issues
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Generic Drugs
ZS-9 Received a CRL Which Strengthens Veltassa''s Commercial Potential in Our View; Reiterate OUTPERFORM and $51 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00
Industry: Medical - Generic Drugs
April Prescriptions Reflect Physicians Testing Veltassa Prior to Widespread Change of Practice
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Generic Drugs
Veltassa New Starts Growth Pauses in April; Affirm Buy on Expected Weakness
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00